News Releases

- Partnership covers three IDEAYA Synthetic Lethality programs - MAT2A, Pol Theta and Werner Helicase, and will explore combinations between IDEAYA and GSK programs

Clinical combination of IDE196, a PKC inhibitor, and binimetinib, a MEK inhibitor, to be investigated in patients with solid tumors that harbor GNAQ or GNA11 hotspot mutations, including Metastatic Uveal Melanoma, Cutaneous Melanoma, and Colorectal Cancer

Chief Executive Officer Yujiro Hata will present key research highlights on Synthetic Lethality today, January 15, 2020, at 5:00 pm PT (8:00 pm ET) at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco

- Targeting initiation of Phase 2 single-arm potentially registration-enabling clinical trial in MUM in Q1 2020, potentially coinciding with Phase 2 introduction of tablet formulation

- Robust enrollment, with 27 total patients enrolled in the Phase 1 dose escalation portion, including 12 patients in MUM DLT cohorts, 14 patients in MUM overflow cohort, and 1 GNA11 cutaneous melanoma patient in non-MUM GNAQ/11 cohort

- Update on Phase 1 Dose-Escalation portion of ongoing Phase 1/2 clinical trial, with specific focus on dosing schema, patient enrollment, and safety data, to be presented at SMR on November 20, 2019

- Single-arm Phase 2 clinical trial may be adequate to support an NDA seeking Accelerated Approval for IDE196 monotherapy in metastatic uveal melanoma (MUM)

Dr. Paul Barsanti joins as Vice President, Head of Drug Discovery

- FDA feedback from End‑of‑Phase 1 meeting indicates IDEAYA's proposed single-arm Phase 2 clinical trial may be adequate to support an NDA seeking Accelerated Approval for IDE196 monotherapy in metastatic uveal melanoma (MUM)